| For: | Zeng ZH, Liu JQ, Zhang M, Qiu CL, Xu ZY. Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. World J Gastroenterol 2025; 31(26): 109285 [PMID: 40678712 DOI: 10.3748/wjg.v31.i26.109285] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v31/i26/109285.htm |
| Number | Citing Articles |
| 1 |
Shuqi Yang, Liting Zhan, Zimei Wan, Xueping Yu. Pradefovir mesylate and tenofovir amibufenamide for chronic hepatitis B: a systematic review and pragmatic treatment algorithm. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1862886
|
| 2 |
Jiarui Zheng, Yuxuan Song, Bo Feng, Yandi Xie. Real-world effectiveness and safety of tenofovir amibufenamide in treatment-naïve chronic hepatitis B: a 48-week retrospective cohort study. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1956363
|
| 3 |
Yinong Feng, Li Zhou, Shaoyuan Shi, Zehong Wang, Xuanxuan Wang, Fan Du. Effectiveness and safety of tenofovir alafenamide in chronic hepatitis B patients over 30 years old with positive hepatitis B virus DNA: a double-center retrospective study. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1680839
|
| 4 |
Yuhan Zeng, Danna Jiang, Lei Guo, Yizhang Chen, Jialu Weng, Xiaohan Liu, Sunting Qin, Mengyu Kong, Ziye Zhou, Xiuhua Zhang. Efficacy and Cost-Effectiveness Analyses of Entecavir versus Tenofovir Amibufenamide in Patients with Chronic Hepatitis B. Drug Design, Development and Therapy 2026; doi: 10.2147/DDDT.S553277
|